Ana M Castejon
Overview
Explore the profile of Ana M Castejon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Omidian H, Wilson R, Castejon A
Pharmaceuticals (Basel)
. 2025 Jan;
18(1).
PMID: 39861188
Peptide-loaded poly(lactide-co-glycolide) (PLGA) nanocarriers represent a transformative approach to addressing the challenges of peptide-based therapies. These systems offer solutions to peptide instability, enzymatic degradation, and limited bioavailability by providing controlled...
2.
Hohmann N, Watterson T, Zou C, Filtz T, Castejon A, Warholak T, et al.
Am J Pharm Educ
. 2024 Dec;
89(2):101342.
PMID: 39667595
Objective: To inform program development, the American Association of Colleges of Pharmacy (AACP) Graduate Education Special Interest Group Colleagues in Training Committee (CITC) investigated the professional development needs of graduate...
3.
Dixon S, Oconnor A, Brooks-Noreiga C, Clark M, Levy A, Castejon A
Cancer Chemother Pharmacol
. 2024 Jun;
94(1):1-23.
PMID: 38914751
Glioblastoma multiforme (GBM) is a highly aggressive and incurable disease accounting for about 10,000 deaths in the USA each year. Despite the current treatment approach which includes surgery with chemotherapy...
4.
Mobasher M, Ansari R, Castejon A, Barar J, Omidi Y
Biochim Biophys Acta Gen Subj
. 2024 Jan;
1868(3):130558.
PMID: 38185238
The effectiveness of messenger RNA (mRNA) vaccines, especially those designed for COVID-19, relies heavily on sophisticated delivery systems that ensure efficient delivery of mRNA to target cells. A variety of...
5.
Omidi Y, Mobasher M, Castejon A, Mahmoudi M
J Drug Target
. 2022 Mar;
30(7):687-708.
PMID: 35321601
Breast cancer is considered as the second major cause of death among women with a high mortality rate worldwide. The exceptionally fast rate of metastasis, the emergence of drug-resistant mechanisms,...
6.
Goshtasbi H, Pakchin P, Movafeghi A, Barar J, Castejon A, Omidian H, et al.
Neurochem Int
. 2021 Dec;
153:105268.
PMID: 34954260
The brain shows a high sensitivity to oxidative stress (OS). Thus, the maintenance and homeostasis of the brain, in particular neural cells, regarding the reduction-oxidation (redox) situation is crucial for...
7.
Alanazi M, Havranek T, Bakos J, Cubeddu L, Castejon A
Endocr Regul
. 2020 Aug;
54(3):172-182.
PMID: 32857718
Objectives: Oxytocin (OXT) participates in various physiological functions ranging from reproduction to social and non-social behaviors. Recent studies indicate that OXT affects cell growth and metabolism. Here we characterized the...
8.
Karhu E, Zukerman R, Eshraghi R, Mittal J, Deth R, Castejon A, et al.
Nutr Rev
. 2019 Dec;
78(7):515-531.
PMID: 31876938
Autism spectrum disorder (ASD) is an increasingly prevalent neurodevelopmental disorder with considerable clinical heterogeneity. With no cure for the disorder, treatments commonly center around speech and behavioral therapies to improve...
9.
Gazova A, Valaskova S, Zufkova V, Castejon A, Kyselovic J
J Tradit Complement Med
. 2019 Apr;
9(2):138-142.
PMID: 30963048
Aim: The safety and effectiveness of a preparation containing a mix of Cucurbita Pepo Seed extract, Equisetum arvense and Linum usitatissimum - Flax A (CELcomplex) on stress urinary incontinence (SUI)...
10.
Bakos J, Bacova Z, Grant S, Castejon A, Ostatnikova D
Neuromolecular Med
. 2015 May;
17(3):297-304.
PMID: 25989848
Autism spectrum disorder is a heterogeneous disease, and numerous alterations of gene expression come into play to attempt to explain potential molecular and pathophysiological causes. Abnormalities of brain development and...